Inici › Leucèmia limfoblàstica aguda › Tennessee › Memphis
Assaigs clínics de Leucèmia limfoblàstica aguda a Memphis, TN
16 estudis de Leucèmia limfoblàstica aguda busquen participants en centres de Memphis i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors
ReclutantVoluntaris sans benvinguts
- St. Jude Children's Research Hospital, Memphis
Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
ReclutantFase 1
- St. Jude Children's Research Hospital, Memphis
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
ReclutantFase 1
- St. Jude Children's Research Hospital, Memphis
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutantFase 1/2
- Saint Jude Children's Research Hospital, Memphis
Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia
Reclutant
- St. Jude Children's Research Hospital, Memphis
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
ReclutantFase 2
- St. Jude Children's Research Hospital, Memphis
Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma
Reclutant
- St. Jude Children's Research Hospital, Memphis
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
ReclutantFase 4
- St. Jude Children's Research Hospital, Memphis
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutantEstudi observacional
- St. Jude Childrens Research Hospital, Memphis
Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
ReclutantFase 2
- St. Jude Children's Research Hospital, Memphis
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
ReclutantFase 1/2
- St. Jude Children's Research Hospital, Memphis
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
ReclutantFase 1
- St. Jude Children's Research Hospital, Memphis
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
ReclutantFase 2
- St. Jude Children's Research Hospital, Memphis
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
ReclutantFase 1
- St. Jude Children's Research Hospital, Memphis
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
ReclutantFase 2
- St. Jude Children's Research Hospital, Memphis
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
ReclutantFase 1
- St. Jude Children's Research Hospital, Memphis
Assaigs de Leucèmia limfoblàstica aguda en altres ciutats
- Houston, TX28 estudis
- New York City, NY24 estudis
- Baldwin Park, CA21 estudis
- Seattle, WA21 estudis
- Chicago, IL19 estudis
- Atlanta, GA19 estudis
- Philadelphia, PA16 estudis
- Washington, DC16 estudis
- Boston, MA15 estudis
- Los Angeles, CA14 estudis
- Durham, NC13 estudis
- Mountain View, CA13 estudis
Altres estudis a Memphis
- Càncer (tots els tipus)31 estudis
- Càncer de pulmó de cèl·lules no petites23 estudis
- Càncer de mama22 estudis
- Càncer de pulmó18 estudis
- Anèmia falciforme18 estudis
- Leucèmia mieloide aguda15 estudis
- Insuficiència cardíaca13 estudis
- Càncer colorrectal11 estudis
- Sarcoma de teixit tou11 estudis
- Melanoma11 estudis
- Càncer de pròstata11 estudis
- Osteosarcoma10 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.